Gil M Labrucherie has bought stock on 3 days since May 2022

Gil M. Labrucherie, CFA, J.D. is a biopharmaceutical finance executive and corporate insider who serves as Chief Financial Officer of Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotech company focused on G protein-coupled receptor (GPCR) drug discovery.( Appointed CFO in January 2025, he brings more than 25 years of senior leadership experience in finance and legal roles across public biopharmaceutical and technology companies and has raised over $1.5 billion in private and public equity capital while helping generate more than $1 billion in realized value from strategic partnering transactions.( As CFO, he oversees Septerna’s financial strategy and reporting as the company advances its GPCR pipeline, and he is also a noted insider in Septerna’s public filings, having recently acquired company common stock through multiple open-market purchases.(

Before joining Septerna, Labrucherie served as Chief Financial Officer and Chief Business Officer at ACELYRIN and previously as Chief Financial Officer and Chief Operating Officer at Nektar Therapeutics, where he also held earlier roles including Senior Vice President and General Counsel, leading functions spanning finance, public reporting, strategic planning, legal, intellectual property, government affairs, IT, and supply chain.( Earlier in his career, he held executive leadership roles at high-growth technology companies and began his professional career as a corporate associate at Wilson Sonsini Goodrich & Rosati.( Labrucherie currently serves on the board of Rezolute, Inc., holds a J.D. from the University of California, Berkeley School of Law and a B.A. from the University of California, Davis, and is both a CFA charterholder and a member of the State Bar of California.(

Written by Perplexity from public sources.